Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etokimab in severe eosinophilic asthma
NCT03469934Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of etokimab in eosinophilic asthma (EA), sponsored by AnaptysBio, Inc.. Started Nov 2017; status: completed.
02
Drugs
etokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03469934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469934.